TY - JOUR
T1 - Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas
AU - Li, Yunyan
AU - Cui, Ziyang
AU - Song, Xiaole
AU - Chen, Yeqing
AU - Li, Cang
AU - Shi, Junfeng
AU - Qian, Wenkang
AU - Ren, Guoxin
AU - Zhou, Jiang
AU - Li, Chunpu
AU - Ma, Xiaoqing
AU - Chen, Yifan
AU - Jia, Dongdong
AU - Zhang, Yongli
AU - Zhang, Zhilin
AU - Zhang, Ronghao
AU - Zhang, Zhaotian
AU - Chen, Yong
AU - Xu, Zhixiang
AU - Chen, Wantao
AU - Miao, Xiao
AU - Yu, Hongmeng
AU - Chen, Jianxin
AU - Wang, Kai
AU - Goding, Colin R.
AU - Wei, Zhi
AU - Li, Tao
AU - Cui, Rutao
N1 - Publisher Copyright:
© 2025 The Authors; Published by the American Association for Cancer Research.
PY - 2025/6/15
Y1 - 2025/6/15
N2 - Purpose: To identify the specific intratumoral and microenvironmental heterogeneity of acral melanoma (AM) and mucosal melanoma (MM), we aimed to delineate their distinct cellular compositions, evolutionary trajectories, and subtype-specific therapeutic strategies. Experimental Design: Single-cell transcriptomic and genomic landscapes were analyzed across 42 melanoma (28 AM, 11 MM, and 3 nonacral cutaneous melanoma) samples, supplemented by in vitro and in vivo validation. Tumor and stromal cells were profiled using single-cell RNA sequencing, whole-exome sequencing, and functional assays, including transwell migration, co-culture systems, and xenograft models. Results: Tumor cells exhibited divergent evolutionary routes, with MM dominated by MGP+/PCOLCE+ subpopulations showing high epithelial-to-mesenchymal transition potential. MM displayed elevated neutrophil infiltration and CXCL3+ tumor-associated macrophages, whereas AM was enriched with PI16+ cancerassociated fibroblasts promoting tumor proliferation. Molecular classification revealed MM subtypes: an antigen-presenting subtype linked to favorable outcomes and a proliferative subtype associated with recurrence. TIGIT+ regulatory T cells were enriched in AM, suggesting targeted inhibition potential. Genomic analysis connected BRAF/NRAS mutations to ALDOA+ stem-like tumor cells and identified prostaglandin D2 synthetase as a therapeutic target in triple–wild-type/melanomas. Conclusions: Our study provides a comprehensive comparison of AM and MM, uncovering subtype-specific stromal– immune interactions and molecular programs. The findings highlight actionable targets (e.g., TIGIT in AM and CXCL3+ macrophages in MM) and propose a framework for precision therapies, biomarker-driven trials, and risk stratification to improve outcomes in these aggressive melanomas.
AB - Purpose: To identify the specific intratumoral and microenvironmental heterogeneity of acral melanoma (AM) and mucosal melanoma (MM), we aimed to delineate their distinct cellular compositions, evolutionary trajectories, and subtype-specific therapeutic strategies. Experimental Design: Single-cell transcriptomic and genomic landscapes were analyzed across 42 melanoma (28 AM, 11 MM, and 3 nonacral cutaneous melanoma) samples, supplemented by in vitro and in vivo validation. Tumor and stromal cells were profiled using single-cell RNA sequencing, whole-exome sequencing, and functional assays, including transwell migration, co-culture systems, and xenograft models. Results: Tumor cells exhibited divergent evolutionary routes, with MM dominated by MGP+/PCOLCE+ subpopulations showing high epithelial-to-mesenchymal transition potential. MM displayed elevated neutrophil infiltration and CXCL3+ tumor-associated macrophages, whereas AM was enriched with PI16+ cancerassociated fibroblasts promoting tumor proliferation. Molecular classification revealed MM subtypes: an antigen-presenting subtype linked to favorable outcomes and a proliferative subtype associated with recurrence. TIGIT+ regulatory T cells were enriched in AM, suggesting targeted inhibition potential. Genomic analysis connected BRAF/NRAS mutations to ALDOA+ stem-like tumor cells and identified prostaglandin D2 synthetase as a therapeutic target in triple–wild-type/melanomas. Conclusions: Our study provides a comprehensive comparison of AM and MM, uncovering subtype-specific stromal– immune interactions and molecular programs. The findings highlight actionable targets (e.g., TIGIT in AM and CXCL3+ macrophages in MM) and propose a framework for precision therapies, biomarker-driven trials, and risk stratification to improve outcomes in these aggressive melanomas.
UR - https://www.scopus.com/pages/publications/105008785935
UR - https://www.scopus.com/pages/publications/105008785935#tab=citedBy
U2 - 10.1158/1078-0432.ccr-24-3164
DO - 10.1158/1078-0432.ccr-24-3164
M3 - Article
C2 - 40192737
AN - SCOPUS:105008785935
SN - 1078-0432
VL - 31
SP - 2495
EP - 2514
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -